{"database":"biostudies-other","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Lucian Smith"],"journal":["PLoS computational biology"],"pagination":["e1006778"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/MODEL1909170002"],"repository":["biostudies-other"],"additional_accession":["31306418"],"pubmed_authors":["Lucian Smith","Szeyi Ng"]},"is_claimable":false,"name":"Perez-Garcia19 - Computational design of improved standardized chemotherapy protocols for grade 2 oligodendrogliomas","description":"This is a model built by COPASI4.24(Build 197)This a model from the article: Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomasVíctor M. Pérez-García, Luis E. Ayala-Hernández, Juan Belmonte-Beitia, Philippe Schucht, Michael Murek, Andreas Raabe,  Juan Sepúlveda. PLoS Comput Biol. 2019 Jul; 15(7): e1006778.Abstract: Here we put forward a mathematical model describing the response of low-grade (WHO grade II) oligodendrogliomas (LGO) to temozolomide (TMZ). The model describes the longitudinal volumetric dynamics of tumor response to TMZ of a cohort of 11 LGO patients treated with TMZ. After finding patient-specific parameters, different therapeutic strategies were tried computationally on the ‘in-silico twins’ of those patients. Chemotherapy schedules with larger-than-standard rest periods between consecutive cycles had either the same or better long-term efficacy than the standard 28-day cycles. The results were confirmed in a large trial of 2000 virtual patients. These long-cycle schemes would also have reduced toxicity and defer the appearance of resistances. On the basis of those results, a combination scheme consisting of five induction TMZ cycles given monthly plus 12 maintenance cycles given every three months was found to provide substantial survival benefits for the in-silico twins of the 11 LGO patients (median 5.69 years, range: 0.67 to 68.45 years) and in a large virtual trial including 2000 patients. We used 220 sets of experiments in-silico to show that a clinical trial incorporating 100 patients per arm (standard intensive treatment versus 5 + 12 scheme) could demonstrate the superiority of the novel scheme after a follow-up period of 10 years. Thus, the proposed treatment plan could be the basis for a standardized TMZ treatment for LGO patients with survival benefits.This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team.For more information see the terms of use.To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92","dates":{"release":"2019-09-17T00:00:00Z","modification":"2025-07-15T09:50:43.475Z","creation":"2025-03-29T21:42:40.437Z"},"accession":"MODEL1909170002","cross_references":{"sbo":["SBO:0000179"],"biomodels___db":["BIOMD0000000814"],"pubmed":["31306418"],"ncit":["C25401","C1244","C41185","C15632","C13413"],"mamo":["MAMO_0000046"],"go":["GO:0040007"],"efo":["0000632","0000311"]}}